Grover’s disease in patients with chronic renal failure receiving hemodialysis: Clinicopathologic review of 4 cases

1999 ◽  
Vol 41 (6) ◽  
pp. 1029-1033 ◽  
Author(s):  
Josep M. Casanova ◽  
Ramon M. Pujol ◽  
Rosa Taberner ◽  
Ramón Egido ◽  
Elvira Fernández ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Grover’S Disease

scholarly journals Grover’s disease: a rare bullous dermatosis spontaneously regressing

2021 ◽  
Vol 5 (4) ◽  
pp. 75-77
Author(s):  
Sara Bouadella
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Skin Eruption ◽  
Female Patient ◽  
Hematological Malignancies ◽  
Middle Aged ◽  
Fever Episode ◽  
Bullous Dermatosis ◽  
Grover’S Disease

Grover's diseaseis an itchy acantholytic disorder occurring on the trunk of middle-aged men. It is a transient dermatosis of unknown cause manifesting clinically as a papular skin eruption located usually on the anterior chest and abdomen and histologically with dyskeratosis and acantholysis. This disease has occasionally been reported in patients with chronic renal failure, some infections, hematological malignancies, and many other anomalies. We report herein a new case of Grover's disease that developed in a female patient after a fever episode.

scholarly journals Grover's Disease after Heart Transplantation: A Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Giovanbattista Ippoliti ◽  
Marco Paulli ◽  
Marco Lucioni ◽  
Andrea Maria D'Armini ◽  
Marinella Lauriola ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Renal Failure ◽  
Case Report ◽  
Chronic Renal Failure ◽  
Heart Transplantation ◽  
Spontaneous Remission ◽  
Hematologic Malignancies ◽  
Sudden Onset ◽  
Transplant Evaluation ◽  
Grover’S Disease

Grover's disease is a transient acantholytic dermatosis of unknown cause, manifesting clinically as a papular skin eruption that is usually located on the anterior chest and abdomen. Histologically characterized by an acantholytic pattern, it has been associated with numerous disorders, including hematologic malignancies, chronic renal failure, and HIV infection, as well as with chemotherapy and bone marrow and/or kidney transplant. Evaluation of followup and treatment is often complicated by spontaneous remission and the occasionally fluctuant course of the disease. Here we report the case of a patient with sudden onset of Grover's disease after heart transplantation. To the best of our knowledge, this is the first observation of Grover's disease as diagnosed after heart transplantation.

Variations in the Lipid Profile of Patients with Chronic Renal Failure, Treated with Folic Acid

2003 ◽  
Vol 73 (3) ◽  
pp. 215-220 ◽  
Author(s):  
de Gómez Dumm ◽  
Giammona ◽  
Touceda
Keyword(s):  
Renal Failure ◽  
Folic Acid ◽  
Chronic Renal Failure ◽  
Density Lipoprotein ◽  
Plasma Homocysteine ◽  
Lipid Profiles ◽  
Erythrocyte Membranes ◽  
Favorable Effect ◽  
High Dose ◽  
Acid Therapy

Dyslipidemia and increases in plasma homocysteine usually occur at end-stage renal disease; both are recognized as risk factors for atherosclerosis. Folate administration reduces homocysteine concentration. In this study we determined the effect of a high dose of folic acid (40 mg intravenous injection three times a week) on plasma and red blood cell lipid profiles in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (baseline) and after 21, 42, and 64 days of treatment. Folic acid supplementation decreased plasma homocysteine. Plasma triglyceride levels decreased whereas polyunsaturated fatty acid values increased after 21 days; then they returned to baseline levels at the end of treatment. Total cholesterol and low-density lipoprotein (LDL) cholesterol were higher than those of the baseline during all the study, whereas high-density lipoprotein (HDL) cholesterol was reduced. In erythrocyte membranes, folic acid therapy enhanced cholesterol/phospholipid ratios and the fluorescence anisotropy of diphenyl-hexatriene. We conclude that large doses of folic acid produce a favorable effect, reducing plasma homocysteine levels and protecting patients from atherosclerosis. However, as this therapy induces significant alterations in both plasma and erythrocyte membrane lipid profiles, plasma lipid values should be controlled throughout the treatment of patients with renal failure.

Sign in / Sign up

Export Citation Format

Share Document